手机看黄色大片1024,亚洲v无码一区二区三区四区观看,黄真人在线观看高清无码,极品嫩模大尺度av在线播放免费观看

產品資料

NCI-H23細胞

如果您對該產品感興趣的話,可以
產品名稱: NCI-H23細胞
產品型號: NCI-H23
產品展商: HZbscience
產品文檔: 無相關文檔

簡單介紹

NCI-H23細胞應如何避免細胞污染,細胞污染的種類可分成**、酵母菌、霉菌、病毒和霉漿菌。主要的污染原因為無菌操作技術不當、操作室環境不佳、污染之血清和污染之細胞等。嚴格之無菌操作技術、清潔的環境、與品質良好之細胞來源和培養基配制是減低污染之*好方法。NCI-H23細胞何時須更換培養基?視細胞生長密度而定,或遵照細胞株基本數據上之更換時間,按時更換培養基即可。


NCI-H23細胞  的詳細介紹

NCI-H23細胞

細胞形態: 上皮樣

是否是腫瘤細胞: 1

物種來源: 人

器官來源: 肺

生長狀態: 貼壁生長

ATCC Number: CRL-5800?

數量: 大量

相關**: 非小細胞肺癌

運輸方式: 凍存運輸

年限: 51 years

Designations: NCI-H23 [H23]

NCI-H23細胞Depositors: AF Gazdar, JD Minna

Biosafety Level: 1

Shipped: frozen

Medium & Serum: See Propagation

Growth Properties: adherent

Organism: Homo sapiens

Morphology: epithelial


Source: Organ: lung

Disease: adenocarcinoma; non-small cell lung cancer

Permits/Forms: In addition to the MTA mentioned above, other ATCC and/or regulatory permits may be required for the transfer of this ATCC material. Anyone purchasing ATCC material is ultimately responsible for obtaining the permits. Please click here for information regarding the specific requirements for shipment to your location.

Restrictions: NCI-H23細胞The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. A. Gazdar and Dr. J. Minna and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 699-8056, FAX (214) 688-7233.

Oncogene: myc +; src +; abl +; erb +; ras +; sis -

DNA Profile (STR): Amelogenin: X

CSF1PO: 10

D13S317: 12

D16S539: 11

D5S818: 12,13

D7S820: 9,10

THO1: 6

TPOX: 8,9

vWA: 16,17

Age: 51 years

Gender: male

Ethnicity: Black

Comments: NCI-H23細胞This line was derived from a lung cancer obtained from a patient prior to therapy.

The cells carry the K-ras 12 mutation, and there is a mutation in codon 246 (ATC -> ATG, isoleucine -> methionine) of the p53 gene.

There is expression of C-myc, L-myc, v-src, v-abl, v-erb B, c-raf 1, Ha-ras, Ki-ras and N-ras RNAs.

The cells express heterogeneous mRNA expression for PDGF A and B chain, transforming growth factor alpha and beta and the epidermal growth factor receptor (EGFR).

NCI-H23 exhibits a high degree of c-myc DNA amplification (20-fold) but no detectable amplification of c-myc RNA.

The cells stain positive for keratins 5+8 and 18 and vimentin but are negative for neurofilament.

NCI-H23 cells are L-dopa decarboxylase-negative.

They have a reported colony forming efficiency of 9.7% in soft agarose.

Propagation: ATCC complete growth medium: The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.

Temperature: 37.0°C

Subculturing: Subcultivation Ratio: A subcultivation ratio of 1:3 to 1:6 is recommended

Medium Renewal: Every 2 to 3 days

Remove spent medium, and add fresh 0.25% trypsin, 0.03% EDTA solution for 2 to 3 minutes at room temperature.

Remove the trypsin and incubate the flask at 37C for 5 to 10 minutes or until the cells detach.

Add fresh medium, aspirate and dispense into new flasks.

Preservation: NCI-H23細胞Culture medium, 95%; DMSO, 5%

Doubling Time: 38 hrs

Related Products: Recommended medium (without the additional supplements or serum described under ATCC Medium):ATCC 30-2001

recommended serum:ATCC 30-2020

References: 1805: Little CD, et al. Amplification and expression of the c-myc oncogene in human lung cancer cell lines. Nature 306: 194-196, 1983. PubMed: 6646201

1806: Takahashi T, et al. p53: A frequent target for genetic abnormalities in lung cancer. Science 246: 491-494, 1989. PubMed: 2554494

22403: Mitsudomi T, et al. p53 gene mutations in non-small-cell lung cancer cell lines and their correlation with the presence of ras mutations and clinical features. Oncogene 7: 171-180, 1992. PubMed: 1311061

22434: Brower M, et al. Growth of cell lines and clinical specimens of human non-small cell lung cancer in a serum-free defined medium. Cancer Res. 46: 798-806, 1986. PubMed: 3940644

22465: Broers JL, et al. Spontaneous changes in intermediate filament protein expression patterns in lung cancer cell lines. J. Cell Sci. 91: 91-108, 1988. PubMed: 2473086

22868: Forsberg K, et al. Expression of functional PDGF beta receptors in a human large-cell lung- carcinoma cell line. Int. J. Cancer 53: 556-560, 1993. PubMed: 8382192

23036: Gazdar AF, et al. NCI-H23細胞Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 40: 3502-3507, 1980. PubMed: 6108156

23570: . NCI-Navy Medical Oncology Branch Cell Line Supplement. J. Cell. Biochem. suppl. 24: 1996..

24389: . . Lung Cancer 4: 155-161, 1988.

滬公網安備 31011702004356號